Coherus Hoping For Expedited FDA Review Of Pegfilgrastim On-Body

Biosimilar Humira Sales Won’t Accelerate Until 2025; Pleased With Ranibizumab Execution

 
• By Dean Rudge
  
Clocks
• Source: Shutterstock: elwynn
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products